

Pharmaceutical Management Agency
New Zealand
Pharmaceutical Schedule

Section H Update

for Hospital Pharmaceuticals

August 2024

The logo for PHARMAC, featuring the word "PHARMAC" in a bold, uppercase, sans-serif font, with "TE PĀTAKA WHAIORANGA" in a smaller, uppercase, sans-serif font below it. The logo is centered within a white circle that overlaps a large, stylized graphic of white wavy lines on a grey background.

PHARMAC
TE PĀTAKA WHAIORANGA

Contents

Summary of decisions effective 1 August 2024.....	3
Section H changes to Part II	7
Index.....	15

Summary of decisions

EFFECTIVE 1 AUGUST 2024

- Adrenaline (Hameln) inj 1 in 1,000, 1 ml ampoule – new listing
- Amino acid formula (without lysine) powder, 13.1 g protein, 50.1 g carbohydrate, 23 g fat and 3.7 g fibre per 100 g, 400 g can (GA1 Anamix Infant) and powder (neutral) 5 g protein, 5.4 g carbohydrate, 2.3 g fat and 2 g fibre per 18 g sachet (GA1 Anamix Junior) – new listing
- Amino acid formula (without methionine) powder (unflavoured) 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can (HCU Anamix Infant); powder (neutral), 10 g protein, 11.5 g carbohydrate and 4.5 g fat per 36 g sachet (HCU Anamix Junior); liquid (orange), 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle (HCU Anamix Junior LQ); liquid (juicy berries), 20 g protein, 9.3 g carbohydrate, 0.44 g fat and 0.44 g fibre per 125 ml bottle (HCU Lophlex LQ) and powder (neutral) 39 g protein and 34 g carbohydrate per 100 g, 500 g can (XMET Maxamum) – new listing
- Amino acid formula (without isoleucine, leucine and valine) powder (unflavoured) 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can (MSUD Anamix Infant); powder (neutral) 10 g protein, 11.5 g carbohydrate and 4.5 g fat per 36 g sachet (MSUD Anamix Junior); liquid (orange) 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle (MSUD Anamix Junior LQ); liquid (juicy berries), 20 g protein, 8.8 g carbohydrate, 0.44 g fat and 0.5 g fibre per 125 ml pouch (MSUD Lophlex LQ 20); powder (orange) 39 g protein and 34 g carbohydrate per 100 g, 500 g can (MSUD Maxamum) and powder (unflavoured) 39 g protein and 34 g carbohydrate per 100 g, 500 g can (MSUD Maxamum) – new listing
- Amino acid formula (without phenylalanine) tab 8.33 mg (Phlexy-10); powder (unflavoured), 5 g protein, 4.8 g carbohydrate per 12.5 g sachets (PKU First Spoon); powder (neutral) 20 g protein, 3.8 g carbohydrate and 0.23 g fibre per 28 g sachet (PKU Lophlex Powder); powder (berry) 20 g protein, 3.8 g carbohydrate and 0.23 g fibre per 28 g sachet (PKU Lophlex Powder); powder (orange) 20 g protein, 3.8 g carbohydrate and 0.23 g fibre per 28 g sachet (PKU Lophlex Powder); liquid (juicy berries) 10 g protein, 4.4 g carbohydrate and 0.25 g fibre per 100 ml, 62.5 ml bottle (PKU Lophlex LQ 10); liquid (juicy tropical) 20 g protein, 8.8 g carbohydrate and 0.34 g fibre per 100 ml, 125 ml bottle (PKU Lophlex LQ 20); liquid (juicy berries) 20 g protein, 8.8 g carbohydrate and 0.34 g fibre per 100 ml, 125 ml bottle (PKU Lophlex LQ 20); liquid (juicy orange) 20 g protein, 8.8 g carbohydrate and 0.34 g fibre per 100 ml, 125 ml bottle (PKU Lophlex LQ 20); semi-solid 18.3 g protein, 18.5 g carbohydrate and 0.92 g fibre per 100 g, 109 g pot (PKU Lophlex Sensations 20 (berries)); liquid 6.7 g protein, 5.1 g carbohydrate and 2 g fat per 100 ml, 250 ml carton (Easiphen Liquid); powder (unflavoured) 39 g protein and 34 g carbohydrate per 100 g, 500 g can (XP Maxamum); powder (orange) 39 g protein and 34 g carbohydrate per 100 g, 500 g can (XP Maxamum); powder

continued...

Summary of decisions – effective 1 August 2024 (continued)

continued...

- (neutral) 36 g protein, 32 g carbohydrate and 12.5 g fat per 100 g, 36 g sachet (PKU Anamix Junior); powder (vanilla) 36 g protein, 32 g carbohydrate and 12.5 g fat per 100 g, 36 g sachet (PKU Anamix Junior) powder (chocolate) 36 g protein, 32 g carbohydrate and 12.5 g fat per 100 g, 36 g sachet (PKU Anamix Junior); powder (orange) 36 g protein, 32 g carbohydrate and 12.5 g fat per 100 g, 36 g sachet (PKU Anamix Junior) and powder 13.1 g protein, 50.1 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can (PKU Anamix Infant) – new listing
- Amino acid formula (without phenylalanine and tyrosine) powder (neutral) 36 g protein, 32 g carbohydrate and 12.5 g fat per 100 g, 36 g sachet (TYR Anamix Junior); powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can (TYR Anamix Infant) and liquid (orange) 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle (TYR Anamix Junior LQ) and liquid (juicy berries), 20 g protein, 8.8 g carbohydrate, 0.44 g fat and 0.5 g fibre per 125 ml pouch (TYR Lophlex LQ 20) – new listing
 - Amino acid formula (without isoleucine, methionine, threonine and valine) powder 13.1 g protein, 50.1 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can (MMA/PA Anamix Infant) – new listing
 - Amino acid formula (without methionine, threonine and valine) (MMA/PA Anamix Junior) powder (neutral), 5 g protein, 5.4 g carbohydrate, 2.3 g fat and 2.0 g fibre per 18 g sachet – new listing
 - Amoxicillin with clavulanic acid (Curam) granules for oral liq 50 mg with clavulanic acid 12.5 mg per ml, 100 ml – price increase
 - Aprepitant (Emend Tri-Pack) cap 2 × 80 mg and 1 × 125 mg – price decrease and addition of PSS
 - Bimatoprost (Lumigan) eye drops 0.03%, 3 ml – new listing and addition of PSS
 - Bimatoprost (Bimatoprost Multichem) eye drops 0.03%, 3 ml – to be delisted 1 January 2025
 - Bortezomib (DBL Bortezomib) inj 3.5 mg vial – amended restricted criteria
 - Bosentan (Bosentan Dr Reddy's) tab 62.5 mg and 125 mg – price decrease and addition of PSS
 - Calcium folinate (Eurofolc) inj 10 mg per ml, 100 ml vial – new listing
 - Capsaicin (Zo-Rub Osteo) crm 0.025%, 45 g – new listing
 - Capsaicin (Zo-Rub HP) crm 0.075%, 45 g – new listing
 - Chlorhexidine gluconate (health) mouthwash 0.2%, 200 ml – new listing and addition of PSS
 - Clonidine hydrochloride (Catapres) inj 150 mcg per ml, 1 ml ampoule – new listing and addition of PSS
 - Clonidine hydrochloride (Medsurge) inj 150 mcg per ml, 1 ml ampoule – to be delisted 1 January 2025
-

Summary of decisions – effective 1 August 2024 (continued)

- Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine (Infanrix-hexa) inj 30IU diphtheria with 40IU tetanus and 25mcg pertussis toxoids, 25mcg pertussis filamentous haemagglutinin, 8mcg pertactin, 80D-AgU polio virus, 10mcg hepatitis B antigen 10mcg H. influenzae type b with tetanus toxoid 20-40mcg in 0.5ml syringe – amended restriction criteria
- Elemental feed with high medium chain triglycerides (Emsogen) powder (neutral), 12.5 g protein, 60 g carbohydrate and 16.4 g fat per 100 g sachet – new listing
- Eptifibatide (Mylan) inj 2 mg per ml, 10 ml vial – to be delisted 1 October 2024
- Essential amino acid formula (Essential Amino Acid Mix) powder (neutral) 79 g protein per 100 g, 200 g can – new listing
- Glycomacropeptide and amino acid contains some phenylalanine powder 20 g protein, 4.9 g carbohydrate per 33.4 g sachet (PKU GMPro 20 Vanilla); powder (unflavoured) 10 g protein, 4 g carbohydrate per 12.5 g sachet (PKU GMPro Mix-In) and liquid (neutral), 10 g protein, 8.5 g carbohydrate per 250 ml carton (PKU GMPro LQ) – new listing
- Hepatitis B recombinant vaccine (Engerix-B) inj 10 mcg per 0.5 ml prefilled syringe and inj 20 mcg per 1 ml prefilled syringe – amended restriction criteria
- Hyoscine hydrobromide (Scopoderm TTS) patch 1 mg per 72 hours – to be delisted 1 January 2025
- Ipratropium bromide (Pharmascience) nebuliser soln 250 mcg per ml, 2 ml ampoule – new listing
- Lenalidomide (Revlimid) cap 5 mg, 10 mg, 15 mg and 25 mg – amended chemical name and to be delisted 1 February 2025
- Lenalidomide (Viatrix) (Lenalidomide Viatrix) cap 5 mg, 10 mg, 15 mg and 25 mg – new listing and addition of PSS
- Lomustine (Ceenu) cap 10 mg and 40 mg – to be delisted 1 January 2025
- Metabolic Products – amended restriction criteria
- Midazolam (Midazolam-Baxter) inj 1 mg per ml, 5 ml ampoule and inj 5 mg per ml, 3 ml ampoule – new listing and addition of PSS
- Midazolam (Mylan Midazolam and Midazolam Viatrix) inj 1 mg per ml, 5 ml ampoule and inj 5 mg per ml, 3 ml ampoule – to be delisted 1 January 2025
- Midodrine (MAR-Midodrine) tab 2.5 mg and 5 mg – new listing
- Naphazoline hydrochloride (Albalon) eye drops 0.1%, 15 ml – new listing and addition of PSS
- Naphazoline hydrochloride (Naphcon Forte) eye drops 0.1%, 15 ml – to be delisted 1 January 2025
- Octreotide (Omega) inj 100 mcg per ml, 1 ml vial – new listing
- Pomalidomide (Pomolide) cap 1 mg, 2 mg, 3 mg and 4 mg, 14 and 21 cap pack – new listing

Summary of decisions – effective 1 August 2024 (continued)

- Protein free supplement containing carbohydrate, fat with added vitamins and minerals (Energivit) powder (neutral) nil added protein and 67 g carbohydrate per 100 g, 400 g can – new listing
- Risperidone (Risperdal) tab 0.5 mg and 2 mg – new listing
- Testosterone (Androderm) patch 5 mg per day – to be delisted 1 November 2024
- Thalidomide (Thalomid) cap 50 mg and 100 mg – amended restriction criteria

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Section H changes to Part II

Effective 1 August 2024

ALIMENTARY TRACT AND METABOLISM

23	CHLORHEXIDINE GLUCONATE (new listing and addition of PSS) Mouthwash 0.2% – 5% DV Jan-25 to 2027	3.99	200 ml	healthE
----	---	------	--------	----------------

BLOOD AND BLOOD FORMING ORGANS

36	EPTIFIBATIDE (delisting) → Inj 2 mg per ml, 10 ml vial	180.38	1	Mylan
Note – Mylan inj 2 mg per ml, 10 ml vial to be delisted from 1 October 2024.				

CARDIOVASCULAR SYSTEM

45	MIDODRINE (new listing) → Tab 2.5 mg.....	38.23	100	MAR-Midodrine
	→ Tab 5 mg.....	59.98	100	MAR-Midodrine

47	CLONIDINE HYDROCHLORIDE (new listing and addition of PSS) Inj 150 mcg per ml, 1 ml ampoule – 5% DV Jan-25 to 2027	14.10	5	Catapres
Note – Medsurge inj 150 mcg per ml, 1 ml ampoule to be delisted from 1 January 2025.				

52	ADRENALINE (new listing) Inj 1 in 1,000, 1 ml ampoule	25.30	10	Hameln
----	--	-------	----	--------

56	BOSENTAN (↓ price and addition of PSS) → Tab 62.5 mg – 5% DV Jan-25 to 2027	100.00	60	Bosentan Dr Reddy's
	→ Tab 125 mg – 5% DV Jan-25 to 2027	100.00	60	Bosentan Dr Reddy's

HORMONE PREPARATIONS

76	TESTOSTERONE (delisting) Patch 5 mg per day	225.00	30	Androderm
Note – Androderm patch 5 mg per day to be delisted from 1 November 2024.				

INFECTIONS

90	AMOXICILLIN WITH CLAVULANIC ACID (↑ price) Grans for oral liq 50 mg with clavulanic acid 12.5 mg per ml.....	4.65	100 ml	Curam
----	---	------	--------	-------

NERVOUS SYSTEM

116	CAPSAICIN (new listing) → Crm 0.025%	9.75	45 g	Zo-Rub Osteo
121	CAPSAICIN (new listing) → Crm 0.075%	11.95	45 g	Zo-Rub HP

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 August 2024 (continued)

130	APREPITANT (↓ price and addition of PSS) → Cap 2 × 80 mg and 1 × 125 mg – 5% DV Jan-25 to 2027	21.90	3	Emend Tri-Pack
130	HYOSCINE HYDROBROMIDE (delisting) → Patch 1 mg per 72 hours	17.70	2	Scopoderm TTS
Note – Scopoderm TTS patch 1 mg per 72 hours to be delisted from 1 January 2025.				
132	RISPERIDONE (new listing) Tab 0.5 mg..... Tab 2 mg.....	0.72 2.72	20 60	Risperdal Risperdal
139	MIDAZOLAM (new listing and addition of PSS) Inj 1 mg per ml, 5 ml ampoule – 5% DV Jan-25 to 2027 Inj 5 mg per ml, 3 ml ampoule – 5% DV Jan-25 to 2027	7.80 4.75	10 5	Midazolam-Baxter Midazolam-Baxter
Note – Mylan Midazolam and Midazolam Viatris inj 1 mg per ml, 5 ml ampoule and inj 5 mg per ml, 3 ml ampoule to be delisted from 1 January 2025.				

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

146	LOMUSTINE (delisting) Cap 10 mg	132.59	20	Ceenu
	Cap 40 mg	399.15	20	Ceenu
Note – Ceenu cap 10 mg and 40 mg to be delisted from 1 January 2025.				
149	BORTEZOMIB (amended restricted criteria) → Inj 3.5 mg vial – 5% DV May-23 to 2025	74.93	1	DBL Bortezomib
Restricted Initiation – multiple myeloma/amyloidosis plasma cell dyscrasia Either: 1–The patient has plasma cell dyscrasia, not including Waldenström macroglobulinaemia, requiring treatment. symptomatic multiple myeloma; or 2–The patient has symptomatic systemic AL amyloidosis.				
151	LENALIDOMIDE (REVLIMID) (amended chemical name and delisting) → Cap 5 mg	5,122.76	28	Revlimid
	→ Cap 10 mg	4,655.25	21	Revlimid
		6,207.00	28	Revlimid
	→ Cap 15 mg	5,429.39	21	Revlimid
		7,239.18	28	Revlimid
	→ Cap 25 mg	7,627.00	21	Revlimid
Note – Revlimid cap 5 mg, 10 mg, 15 mg and 25 mg, 21 and 28 cap pack to be delisted from 1 February 2025.				

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 August 2024 (continued)

151	LLENALIDOMIDE (VIATRIS) (new listing and addition of PSS)			
	→ Cap 5 mg – 5% DV Feb-25 to 31-Jan-2028	76.92	21	Lenalidomide Viatris
	→ Cap 10 mg – 5% DV Feb -25 to 31-Jan-2028	50.30	21	Lenalidomide Viatris
	→ Cap 15 mg – 5% DV Feb -25 to 31-Jan-2028	62.13	21	Lenalidomide Viatris
	→ Cap 25 mg – 5% DV Feb -25 to 31-Jan-2028	65.09	21	Lenalidomide Viatris
	Restricted			
	Initiation – Plasma cell dyscrasia			
	Any relevant practitioner			
	Both:			
	1 Patient has plasma cell dyscrasia, not including Waldenström macroglobulinaemia, requiring treatment; and			
	2 Patient is not refractory to prior lenalidomide use.			
	Initiation – Myelodysplastic syndrome			
	Any relevant practitioner			
	<i>Re-assessment required after 6 months</i>			
	Both:			
	1 Patient has low or intermediate-1 risk myelodysplastic syndrome (based on IPSS or an IPSS-R score of less than 3.5) associated with a deletion 5q cytogenetic abnormality; and			
	2 Patient has transfusion-dependent anaemia.			
	Continuation – Myelodysplastic syndrome			
	Any relevant practitioner			
	<i>Re-assessment required after 12 months</i>			
	Both:			
	1 Patient has not needed a transfusion in the last 4 months; and			
	2 No evidence of disease progression.			
153	POMALIDOMIDE (new listing)			
	→ Cap 1 mg – 5% DV Aug-24 to 31-Jul-2027	47.45	14	Pomolide
		71.18	21	Pomolide
	→ Cap 2 mg – 5% DV Aug-24 to 31-Jul-2027	94.90	14	Pomolide
		142.35	21	Pomolide
	→ Cap 3 mg – 5% DV Aug-24 to 31-Jul-2027	142.35	14	Pomolide
		213.53	21	Pomolide
	→ Cap 4 mg – 5% DV Aug-24 to 31-Jul-2027	189.81	14	Pomolide
		284.71	21	Pomolide
	Restricted			
	Initiation – Relapsed/refractory plasma cell dyscrasia			
	Any relevant practitioner			
	<i>Re-assessment required after 6 months</i>			
	Both:			
	1 Patient has relapsed or refractory plasma cell dyscrasia, not including Waldenström macroglobulinaemia, requiring treatment; and			
	2 Patient has not received prior funded pomalidomide.			
	Continuation – Relapsed/refractory plasma cell dyscrasia			
	Any relevant practitioner			
	<i>Re-assessment required after 12 months</i>			
	Patient has no evidence of disease progression.			

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 August 2024 (continued)

154	THALIDOMIDE (amended restricted criteria)			
	→ Cap 50 mg	378.00	28	Thalomid
	→ Cap 100 mg	756.00	28	Thalomid
	Restricted Initiation <i>Re-assessment required after 12 months</i> Any of the following Either :			
	1 The patient has plasma cell dyscrasia, not including Waldenström macroglobulinaemia, requiring treatment multiple myeloma ; or			
	2 The patient has systemic AL amyloidosis*; or			
	2‡ The patient has erythema nodosum leprosum.			
	Continuation Patient has obtained a response from treatment during the initial approval period. Notes: Prescription must be written by a registered prescriber in the thalidomide risk management programme operated by the supplier Maximum dose of 400 mg daily as monotherapy or in a combination therapy regimen Indication marked with * is an unapproved indication			

163	CALCIUM FOLINATE (new listing)			
	Inj 10 mg per ml, 100 ml vial	72.00	1	Eurofolic
166	OCTREOTIDE (new listing)			
	Inj 100 mcg per ml, 1 ml vial	48.50	5	Omega

RESPIRATORY SYSTEM AND ALLERGIES

244	IPRATROPIUM BROMIDE (new listing)			
	Nebuliser soln 250 mcg per ml, 2 ml ampoule.....	5.86	10	Pharmascience

SENSORY ORGANS

254	NAPHAZOLINE HYDROCHLORIDE (new listing and addition of PSS)			
	Eye drops 0.1% – 5% DV Jan-25 to 2027	5.65	15 ml	Albalon
	Note – Naphcon Forte eye drops 0.1% to be delisted from 1 January 2025.			
256	BIMATOPROST (new listing and addition of PSS)			
	Eye drops 0.03% – 5% DV Jan-25 to 2027	5.15	3 ml	Lumigan
	Note – Bimatoprost Multichem eye drops 0.03% to be delisted from 1 January 2025.			

Changes to Section H Part II – effective 1 August 2024 (continued)

SPECIAL FOODS

272	Metabolic Products (amended restriction criteria) Restricted Initiation Any of the following Either : 1 For the dietary management of inherited metabolic disease; or 2 Patient has adrenoleukodystrophy; or 3 For use as a supplement to the Ketogenic diet in patients diagnosed with epilepsy.			
272	AMINO ACID FORMULA (WITHOUT LYSINE) (new listing) → Powder, 13.1 g protein, 50.1 g carbohydrate, 23 g fat and 3.7 g fibre per 100 g, 400 g can 260.00	400 g	GA1 Anamix Infant	
	→ Powder (neutral) 5 g protein, 5.4 g carbohydrate, 2.3 g fat and 2 g fibre per 18 g sachet 750.30	30	GA1 Anamix Junior	
273	AMINO ACID FORMULA (WITHOUT METHIONINE) (new listing) → Powder (unflavoured) 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can 260.00	400 g	HCU Anamix Infant	
	→ Powder (neutral), 10 g protein, 11.5 g carbohydrate and 4.5 g fat per 36 g sachet 750.30	30	HCU Anamix Junior	
	→ Liquid (orange), 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle 941.40	36	HCU Anamix Junior LQ	
	→ Liquid (juicy berries), 20 g protein, 9.3 g carbohydrate, 0.44 g fat and 0.44 g fibre per 125 ml bottle 1,684.80	30	HCU Lophlex LQ	
	→ Powder (neutral) 39 g protein and 34 g carbohydrate per 100 g, 500 g can 480.42	500 g	XMET Maxamum	
273	AMINO ACID FORMULA (WITHOUT ISOLEUCINE, LEUCINE AND VALINE) (new listing) → Powder (unflavoured) 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can 260.00	400 g	MSUD Anamix Infant	
	→ Powder (neutral) 10 g protein, 11.5 g carbohydrate and 4.5 g fat per 36 g sachet 750.00	30	MSUD Anamix Junior	
	→ Liquid (orange) 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle 941.40	36	MSUD Anamix Junior LQ	
	→ Liquid (juicy berries), 20 g protein, 8.8 g carbohydrate, 0.44 g fat and 0.5 g fibre per 125 ml pouch 1,684.80	30	MSUD Lophlex LQ 20	
	→ Powder (orange) 39 g protein and 34 g carbohydrate per 100 g, 500 g can 454.71	500 g	MSUD Maxamum	
	→ Powder (unflavoured) 39 g protein and 34 g carbohydrate per 100 g, 500 g can 454.71	500 g	MSUD Maxamum	

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 August 2024 (continued)

274	AMINO ACID FORMULA (WITHOUT PHENYLALANINE) (new listing)		
	→ Tab 8.33 mg.....	99.00	75 Phlexy-10
	→ Powder (unflavoured), 5 g protein, 4.8 g carbohydrate per 12.5 g sachets	234.00	30 PKU First Spoon
	→ Powder (neutral) 20 g protein, 3.8 g carbohydrate and 0.23 g fibre per 28 g sachet	936.00	30 PKU Lophlex Powder
	→ Powder (berry) 20 g protein, 3.8 g carbohydrate and 0.23 g fibre per 28 g sachet	936.00	30 PKU Lophlex Powder
	→ Powder (orange) 20 g protein, 3.8 g carbohydrate and 0.23 g fibre per 28 g sachet	936.00	30 PKU Lophlex Powder
	→ Liquid (juicy berries) 10 g protein, 4.4 g carbohydrate and 0.25 g fibre per 100 ml, 62.5 ml bottle.....	939.00	60 PKU Lophlex LQ 10
	→ Liquid (juicy tropical) 20 g protein, 8.8 g carbohydrate and 0.34 g fibre per 100 ml, 125 ml bottle.....	936.00	30 PKU Lophlex LQ 20
	→ Liquid (juicy berries) 20 g protein, 8.8 g carbohydrate and 0.34 g fibre per 100 ml, 125 ml bottle.....	936.00	30 PKU Lophlex LQ 20
	→ Liquid (juicy orange) 20 g protein, 8.8 g carbohydrate and 0.34 g fibre per 100 ml, 125 ml bottle.....	936.00	30 PKU Lophlex LQ 20
	→ Semi-solid 18.3 g protein, 18.5 g carbohydrate and 0.92 g fibre per 100 g, 109 g pot.....	1,123.20	36 PKU Lophlex Sensations 20 (berries)
	→ Liquid 6.7 g protein, 5.1 g carbohydrate and 2 g fat per 100 ml, 250 ml carton.....	540.00	18 Easiphen Liquid
	→ Powder (unflavoured) 39 g protein and 34 g carbohydrate per 100 g, 500 g can.....	320.00	500g XP Maxamum
	→ Powder (orange) 39 g protein and 34 g carbohydrate per 100 g, 500 g can.....	320.00	500g XP Maxamum
	→ Powder (neutral) 36 g protein, 32 g carbohydrate and 12.5 g fat per 100 g, 36 g sachet	393.00	30 PKU Anamix Junior
	→ Powder (vanilla) 36 g protein, 32 g carbohydrate and 12.5 g fat per 100 g, 36 g sachet	393.00	30 PKU Anamix Junior
	→ Powder (chocolate) 36 g protein, 32 g carbohydrate and 12.5 g fat per 100 g, 36 g sachet	393.00	30 PKU Anamix Junior
	→ Powder (orange) 36 g protein, 32 g carbohydrate and 12.5 g fat per 100 g, 36 g sachet	393.00	30 PKU Anamix Junior
	→ Powder 13.1 g protein, 50.1 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can.....	174.72	400 g PKU Anamix Infant
275	GLYCOMACROPEPTIDE AND AMINO ACID CONTAINS SOME PHENYLALANINE (new listing)		
	→ Powder 20 g protein, 4.9 g carbohydrate per 33.4 g sachet...	936.00	30 PKU GMPro 20 Vanilla
	→ Powder (unflavoured) 10 g protein, 4 g carbohydrate per 12.5 g sachet.....	468.00	30 PKU GMPro Mix-In
	→ Liquid (neutral), 10 g protein, 8.5 g carbohydrate per 250 ml carton	280.80	18 PKU GMPro LQ
275	ESSENTIAL AMINO ACID FORMULA (new listing)		
	→ Powder (neutral) 79 g protein per 100 g, 200 g can	313.73	200 g Essential Amino Acid Mix

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 August 2024 (continued)

275	AMINO ACID FORMULA (WITHOUT PHENYLALANINE AND TYROSINE) (new listing)			
	→ Powder (neutral) 36 g protein, 32 g carbohydrate and 12.5 g fat per 100 g, 36 g sachet	471.00	30	TYR Anamix Junior
	→ Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can	260.00	400 g	TYR Anamix Infant
	→ Liquid (orange) 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle.....	941.40	36	TYR Anamix Junior LQ
	→ Liquid (juicy berries), 20 g protein, 8.8 g carbohydrate, 0.44 g fat and 0.5 g fibre per 125 ml pouch.....	1,684.80	30	TYR Lophlex LQ 20
276	AMINO ACID FORMULA (WITHOUT ISOLEUCINE, METHIONINE, THREONINE AND VALINE) (new listing)			
	→ Powder 13.1 g protein, 50.1 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can	260.00	400 g	MMA/PA Anamix Infant
276	AMINO ACID FORMULA (WITHOUT METHIONINE, THREONINE AND VALINE) (new listing)			
	→ Powder (neutral), 5 g protein, 5.4 g carbohydrate, 2.3 g fat and 2.0 g fibre per 18 g sachet.....	750.30	30	MMA/PA Anamix Junior
279	ELEMENTAL FEED WITH HIGH MEDIUM CHAIN TRIGLYCERIDES (new listing)			
	→ Powder (neutral), 12.5 g protein, 60 g carbohydrate and 16.4 g fat per 100 g sachet.....	47.01	10	Emsogen
279	PROTEIN FREE SUPPLEMENT CONTAINING CARBOHYDRATE, FAT WITH ADDED VITAMINS AND MINERALS (new listing)			
	→ Powder (neutral) nil added protein and 67 g carbohydrate per 100 g, 400 g can.....	49.29	400 g	Energivit

VACCINES

288	DIPHTHERIA, TETANUS, PERTUSSIS, POLIO, HEPATITIS B AND HAEMOPHILUS INFLUENZAE TYPE B VACCINE (amended restriction criteria)			
	→ Inj 30IU diphtheria with 40IU tetanus and 25mcg pertussis toxoids, 25mcg pertussis filamentous haemagglutinin, 8mcg pertactin, 80D-AgU polio virus, 10mcg hepatitis B antigen 10mcg H. influenzae type b with tetanus toxoid 20-40mcg in 0.5ml syringe – 5% DV Dec-24 to 2027	0.00	10	Infanrix-hexa

Restricted

Initiation

Any of the following:

- 1 Up to four doses for children up to and under the age of 10 for primary immunisation; or
- 2 An additional four doses (as appropriate) are funded for (re-) immunisation for children ~~up to and~~ under the age of ~~10~~ **18** who are patients post haematopoietic stem cell transplantation, or chemotherapy; pre or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens; or
- 3 Up to five doses for children up to and under the age of 10 receiving solid organ transplantation.

Note: A course of up-to four vaccines is funded for catch up programmes for children (up to and under the age of 10 years) to complete full primary immunisation. Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 August 2024 (continued)

294	HEPATITIS B RECOMBINANT VACCINE (amended restriction criteria)			
	→ Inj 10 mcg per 0.5 ml prefilled syringe			
	– 5% DV Dec-24 to 2027	0.00	1	Engerix-B
	Restricted			
	Initiation			
	Any of the following:			
	1 For household or sexual contacts of known acute hepatitis B patients or hepatitis B carriers; or			
	2 For children born to mothers who are hepatitis B surface antigen (HBsAg) positive; or			
	3 For children up to and under the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination or require a primary course of vaccination; or			
	4 For HIV positive patients; or			
	5 For hepatitis C positive patients; or			
	6 For patients following non-consensual sexual intercourse; or			
	7 For patients prior to planned immunosuppression for greater than 28 days; or			
	8 For patients following immunosuppression; or			
	9 For solid organ transplant patients; or			
	10 For post-haematopoietic stem cell transplant (HSCT) patients; or			
	11 Following needle stick injury.			
	→ Inj 20 mcg per 1 ml prefilled syringe			
	– 5% DV Dec-24 to 2027	0.00	1	Engerix-B
	Restricted			
	Initiation			
	Any of the following:			
	1 For household or sexual contacts of known acute hepatitis B patients or hepatitis B carriers; or			
	2 For children born to mothers who are hepatitis B surface antigen (HBsAg) positive; or			
	3 For children up to and under the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination or require a primary course of vaccination; or			
	4 For HIV positive patients; or			
	5 For hepatitis C positive patients; or			
	6 For patients following non-consensual sexual intercourse; or			
	7 For patients prior to planned immunosuppression for greater than 28 days; or			
	8 For patients following immunosuppression; or			
	9 For solid organ transplant patients; or			
	10 For post-haematopoietic stem cell transplant (HSCT) patients; or			
	11 Following needle stick injury; or			
	12 For dialysis patients; or			
	13 For liver or kidney transplant patients.			

Index

Pharmaceuticals and brands

A		
ADRENALINE	7	
Albalon	10	
AMINO ACID FORMULA (WITHOUT ISOLEUCINE, LEUCINE AND VALINE)	11	
AMINO ACID FORMULA (WITHOUT ISOLEUCINE, METHIONINE, THREONINE AND VALINE)	13	
AMINO ACID FORMULA (WITHOUT LYSINE)	11	
AMINO ACID FORMULA (WITHOUT METHIONINE)	11	
AMINO ACID FORMULA (WITHOUT METHIONINE, THREONINE AND VALINE)	13	
AMINO ACID FORMULA (WITHOUT PHENYLALANINE) ..	12	
AMINO ACID FORMULA (WITHOUT PHENYLALANINE AND TYROSINE)	13	
AMOXICILLIN WITH CLAVULANIC ACID	7	
Androderm	7	
APREPITANT	8	
B		
BIMATOPROST	10	
BORTEZOMIB	8	
BOSENTAN	7	
Bosentan Dr Reddy's	7	
C		
CALCIUM FOLINATE	10	
CAPSAICIN	7	
Catapres	7	
Ceenu	8	
CHLORHEXIDINE GLUCONATE	7	
CLONIDINE HYDROCHLORIDE	7	
Curam	7	
D		
DBL Bortezomib	8	
DIPHThERIA, TETANUS, PERTUSSIS, POLIO, HEPATITIS B AND HAEMOPHILUS INFLUENZAE TYPE B VACCINE	13	
E		
Easiphen Liquid	12	
ELEMENTAL FEED WITH HIGH MEDIUM CHAIN TRIGLYCERIDES	13	
Emend Tri-Pack	8	
Emsogen	13	
Energivit	13	
Engerix-B	14	
EPTIFIBATIDE	7	
ESSENTIAL AMINO ACID FORMULA	12	
Essential Amino Acid Mix	12	
Eurofolic	10	
G		
GA1 Anamix Infant	11	
GA1 Anamix Junior	11	
GLYCOMACROPEPTIDE AND AMINO ACID CONTAINS SOME PHENYLALANINE	12	
H		
HCU Anamix Infant	11	
HCU Anamix Junior	11	
HCU Anamix Junior LQ	11	
HCU Lophlex LQ	11	
HEPATITIS B RECOMBINANT VACCINE	14	
HYOSCINE HYDROBROMIDE	8	
I		
Infanrix-hexa	13	
IPRATROPIUM BROMIDE	10	
L		
LENALIDOMIDE	8	
LENALIDOMIDE (REVLIMID)	8	
Lenalidomide Viatrix	9	
LENALIDOMIDE (VIATRIS)	9	
LOMUSTINE	8	
Lumigan	10	
M		
MAR-Midodrine	7	
MIDAZOLAM	8	
Midazolam-Baxter	8	
MIDODRINE	7	
MMA/PA Anamix Infant	13	
MMA/PA Anamix Junior	13	
MSUD Anamix Infant	11	
MSUD Anamix Junior	11	
MSUD Anamix Junior LQ	11	
MSUD Lophlex LQ 20	11	
MSUD Maxamum	11	
N		
NAPHAZOLINE HYDROCHLORIDE	10	
O		
OCTREOTIDE	10	
P		
Phlexy-10	12	
PKU Anamix Infant	12	
PKU Anamix Junior	12	
PKU First Spoon	12	
PKU GMPro 20 Vanilla	12	
PKU GMPro LQ	12	
PKU GMPro Mix-In	12	
PKU Lophlex LQ 10	12	
PKU Lophlex LQ 20	12	
PKU Lophlex Powder	12	
PKU Lophlex Sensations 20 (berries)	12	
POMALIDOMIDE	9	
Pomolide	9	

Index

Pharmaceuticals and brands

PROTEIN FREE SUPPLEMENT CONTAINING CARBOHYDRATE, FAT WITH ADDED VITAMINS AND MINERALS	13	Thalomid.....	10
R		TYR Anamix Infant.....	13
Revlimid	8	TYR Anamix Junior.....	13
Risperdal	8	TYR Anamix Junior LQ	13
RISPERIDONE	8	TYR Lophlex LQ 20	13
S		X	
Scopoderm TTS.....	8	XMET Maxamum.....	11
T		XP Maxamum	12
TESTOSTERONE	7	Z	
THALIDOMIDE	10	Zo-Rub HP	7
		Zo-Rub Osteo.....	7

Pharmaceutical Management Agency
Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand
Phone: 64 4 460 4990 - www.pharmac.govt.nz
Email: enquiry@pharmac.govt.nz

ISSN 1179-3708 (Online)

Te Kāwanatanga o Aotearoa [New Zealand Government](#)

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the update.

